A5101709468- Diabetes Management and Research
- Diabetes Treatment and Management
- Diabetes Management and Education
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pancreatic function and diabetes
- Metabolism, Diabetes, and Cancer
- Diabetes and associated disorders
- Pharmacology and Obesity Treatment
- Diet and metabolism studies
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Chronic Disease Management Strategies
- Health Systems, Economic Evaluations, Quality of Life
- Ophthalmology and Eye Disorders
- Blood Pressure and Hypertension Studies
- Thyroid Disorders and Treatments
- T-cell and B-cell Immunology
- Erythrocyte Function and Pathophysiology
- Medication Adherence and Compliance
- Cardiovascular Function and Risk Factors
- Clinical practice guidelines implementation
- Pharmaceutical Practices and Patient Outcomes
- Chronic Kidney Disease and Diabetes
- Obesity, Physical Activity, Diet
- Colorectal Cancer Screening and Detection
- Neurofibromatosis and Schwannoma Cases
Janssen (United States)
2017-2018
Cleveland Clinic
2018
Janssen Scientific Affairs (United States)
2017
University of Washington
2017
Bridgewater College
2014
Ballad Health
2014
The King's College
2014
Laval Mayenne Technopole
2014
Carrier (United States)
2014
Sanofi (United States)
2006-2013
<b>Objectives</b> To investigate potential determinants of severe hypoglycaemia, including baseline characteristics, in the Action to Control Cardiovascular Risk Diabetes (ACCORD) trial and association hypoglycaemia with levels glycated haemoglobin (haemoglobin A<sub>1C</sub>) achieved during therapy. <b>Design</b> Post hoc epidemiological analysis a double 2×2 factorial, randomised, controlled trial. <b>Setting</b> clinics, research primary care clinics. <b>Participants</b> 10 209 251...
To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), sitagliptin (SITA) over 26 weeks, in suboptimally treated (diet exercise) drug-naive patients type 2 diabetes.Patients were randomized to subcutaneous (SC) EQW 2.0 mg + oral placebo (n = 248), MET 2,000 mg/day SC 246), PIO 45 163), or SITA 100 163) for weeks. therapies increased maximum-tolerated dosages. Injections administered weekly, while medication was daily.Baseline...
Aim: The aim of this study was to compare the efficacy and safety once-daily human glucagon-like peptide-1 analogue liraglutide with dipeptidyl peptidase-4 inhibitor sitagliptin, each added metformin, over 52 weeks in individuals type 2 diabetes. Methods: In an open-label, parallel-group trial, metformin-treated participants were randomised 1.2 mg/day (n = 225), 1.8 221) or sitagliptin 100 219) for 26 (main phase). Participants continued same treatment a 26-week extension. Results:...
Highlights•Canagliflozin reduced HbA1c and provided greater weight loss vs glimepiride.•Canagliflozin decreased serum leptin increased adiponectin also IL-6 TNFα glimepiride.•No meaningful changes in biomarkers were seen with may improve adipose tissue function cardiometabolic health.AbstractObjectiveType 2 diabetes obesity are pro-inflammatory states associated risk of cardiovascular disease. Canagliflozin, an SGLT2 inhibitor, demonstrated superiority lowering versus glimepiride less...
Significance Vascular complications are the main cause of morbidity and mortality in diabetic population. Clinical trials show a persistence benefit from early application intensive therapy for glycemic control patients, phenomenon referred to as metabolic memory. The mechanisms underlying memory not fully understood. In this study, using two groups type 1 patients with without development sets genomic DNAs collected 16–17 y apart same we showed persistency DNA methylation over time at key...
Efforts to mimic euglycemia depend upon targets from epidemiologic studies that rely on episodic measurements reduced statistical summaries, leaving open the question, "What is normal glycemia?" We postulated portrayal of was possible through application continuous glucose monitoring (CGM) and a novel analytical tool, ambulatory profile (AGP).Individuals with tolerance (NGT) diabetes used CGM for 30 days. AGP analysis, which graphs data by time without regard date, characterize exposure,...
OBJECTIVE Intensive treatment (INT) of type 1 diabetes reduces the incidence cardiovascular disease (CVD) events compared with conventional (CONV), but it also results in more weight gain. Our objective was to examine whether excessive gain from INT is independently associated subsequent CVD events. RESEARCH DESIGN AND METHODS Quartiles (Q) 1,213 participants aged 18 years and older at enrollment Diabetes Control Complications Trial (DCCT) were determined within randomized groups (INT vs....
Insulin degludec/insulin aspart (IDegAsp) is a soluble coformulation of the novel basal analog insulin degludec (IDeg: 70%) and (IAsp: 30%). We compared safety efficacy IDegAsp, an alternative formulation (AF) (55% IDeg 45% IAsp), glargine (IGlar) in insulin-naïve subjects with type 2 diabetes inadequately controlled oral antidiabetic drugs.In this 16-week, open-label trial, (mean age 59.1 years, A1C 8.5%, BMI 30.3 kg/m(2)) were randomized to once-daily IDegAsp (n = 59), AF or IGlar 60), all...
We and others have described previously a polymorphism at the first position of codon 52 (C52→A52) human thyrotropin receptor (hTSHr) gene. To determine its potential significance, we studied female (n = 100) male 25) patients with autoimmune thyroid disease (Graves' disease, n 91; Hashimoto's thyroiditis, 34) normal individuals [n 121, 69), 52)]. Screening was performed using AciI restriction enzyme digestions PCR-amplified genomic DNA. All polymorphisms were verified by direct DNA...
Purpose The purpose of this study was to investigate the opinions primary care physicians (PCPs) and diabetes specialists on their perceived role in tackling type 2 (T2D) challenges they face, particularly regarding insulin intensification. Methods Six hundred from Germany, Japan, Spain, Turkey, United Kingdom, States were recruited complete an online survey. Screening criteria included T2D patients seen per week (Europe/Japan: all ≥2; States: PCPs ≥5; ≥10) years practice (3—30 years)....
Diabet. Med. 28, 333–337 (2011) Abstract Aims Patient‐reported outcomes from clinical trials offer insight into the impact of disease on health‐related quality life, including treatment satisfaction. This patient‐reported evaluation was a substudy 26‐week randomized, open‐label trial comparing once‐daily injectable human GLP‐1 analogue liraglutide with oral sitagliptin, both added to metformin. The patient reported aimed evaluate satisfaction using Diabetes Treatment Satisfaction...
To compare the effect of intensive versus standard glycemic control strategies on health-related quality life (HRQL) in a substudy Action to Control Cardiovascular Risk Diabetes (ACCORD) trial.
To determine whether women with diabetes undergo fewer screening mammograms than matched control subjects.A total of 424 aged 50-75 years who received their primary care from general internists at a large Midwestern multispecialty group practice were retrospectively studied for frequency mammography August 1997 to January 2000. Two subjects without (n = 845) each case by age, sex, provider, and date visit. The main outcome measure was the percentage undergoing 1 year before 30 days after an...
Although an association between the human leukocyte antigen (HLA) allele DR3 and Graves' disease (GD) is well documented, potential role of non-HLA-linked alleles in susceptibility to GD area active investigation. In attempt study two non-HLA ophthalmopathy, we examined 286 North American Caucasian individuals (145 normal controls 141 with GD) for presence A2 interleukin-1 (IL-1) receptor antagonist gene. addition, a subset this population (83 89 specific polymorphism within exon 5 IL-1...
Blood pressure (BP) is not well controlled in the majority of patients with both diabetes and hypertension. This study was designed to identify predictors BP control hypertension who are seen primary care clinics.This retrospective conducted by identifying a cohort diagnosed before January 1, 2000 (inception) met predefined criteria for at inception received ensuing 3-year period (January 2000, February 31, 2002). Using mean all values between 2002, December subjects were divided into two...
Type 2 diabetes mellitus (T2DM) progression often results in treatment intensification with injectable therapy to maintain glycemic control. Using pilot data from the Initiation of New Injectable Treatment Introduced after Anti-diabetic Therapy Oral-only Regimens study, real-world patterns among T2DM patients initiating insulin glargine or liraglutide were assessed. This was a retrospective analysis claims OptumInsight™ (OI; January 1, 2010 July 30, 2010) and HealthCore® (HC; June health...